Ligand Pharma(DE:LGDN)
€274.00+6.00 (+4.58%)
DE:LGDN
Ligand Pharma ownership
€274.00
At close:+6.00 (+4.58%)
Ligand Pharma (LGDN) Ownership - Who Owns Ligand Pharma?
1 Followers
Ligand Pharma (LGDN) Ownership Overview
- 2.48% Insiders
- 49.39% Mutual Funds
- 14.87% Other Institutional Investors
- 28.56% ETFs
- 4.70% Public Companies and Individual Investors
The ownership structure of Ligand Pharma (DE:LGDN) stock is a mix of institutional, retail, and individual investors. Approximately 92.82% of the company’s stock is owned by Institutional Investors, 2.48% is owned by Insiders, and 4.70% is owned by Public Companies and Individual Investors.
The ownership structure of Ligand Pharma (DE:LGDN) stock is a mix of institutional, retail, and individual investors. Approximately 92.82% of the company’s stock is owned by Institutional Investors, 2.48% is owned by Insiders, and 4.70% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Nov 05, 2026 | Jason Aryeh | $90,237 | |
| Nov 02, 2026 | Jason Aryeh | $676,145 | |
| Aug 13, 2026 | Jason Haas | $2,090,006 | |
| Jun 17, 2026 | Stephen Sabba | $544,830 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Bridgewater Associates, Lp | €795,417 | |
| Dec 31, 2025 | Driehaus Capital Management Llc | €23,128,176 | |
| Dec 31, 2025 | Fisher Asset Management Llc | €24,741,322 | |
| Dec 31, 2025 | Private Capital Management, Llc | €39,495,021 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| BlackRock, Inc. | 3,100,996 | Institution | 15.50% | 942,845,430 |
| Ishares | 2,368,777 | Institution | 11.84% | 720,217,172 |
| Vanguard | 1,839,778 | Institution | 9.20% | 559,377,142 |
| Vanguard Index Funds | 1,549,000 | Institution | 7.74% | 470,967,254 |
| Delaware Group Equity Funds V | 1,541,943 | Institution | 7.71% | 468,821,601 |
| Janus Investment Fund | 792,851 | Institution | 3.96% | 241,063,175 |
| Franklin Custodian Funds | 550,000 | Institution | 2.75% | 167,225,300 |
| Fidelity Securities Fund | 536,865 | Institution | 2.68% | 163,231,656 |
| Spdr | 409,644 | Institution | 2.05% | 124,550,620 |
| Invesco | 314,610 | Institution | 1.57% | 95,655,912 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 1,549,000 | Institution | 7.74% | 470,967,254 |
| Delaware Group Equity Funds V | 1,541,943 | Institution | 7.71% | 468,821,601 |
| Janus Investment Fund | 792,851 | Institution | 3.96% | 241,063,175 |
| Franklin Custodian Funds | 550,000 | Institution | 2.75% | 167,225,300 |
| Fidelity Securities Fund | 536,865 | Institution | 2.68% | 163,231,656 |
| Fidelity Salem Street Trust | 292,379 | Institution | 1.46% | 88,896,665 |
| Lazard Funds Inc | 280,005 | Institution | 1.40% | 85,134,400 |
| Fidelity Concord Street Trust | 273,241 | Institution | 1.37% | 83,077,833 |
| Professionally Managed Portfolios | 271,577 | Institution | 1.36% | 82,571,901 |
| Vanguard Explorer Fund | 234,250 | Institution | 1.17% | 71,222,776 |
FAQ
Who Owns Ligand Pharma (DE:LGDN)?
According to the latest TipRanks data, approximately 92.82% of the company's stock is held by institutional investors, 2.48% is held by insiders, and 4.70% is held by public companies and individual investors.
What percentage of Ligand Pharma (DE:LGDN) stock is held by institutional investors?
According to the latest TipRanks data, approximately 92.82% of Ligand Pharma (DE:LGDN) stock is held by institutional investors: 49.39% by mutual funds, 28.56% by ETFs and 14.87% by other institutional investors.
What percentage of Ligand Pharma (DE:LGDN) stock is held by retail investors?
According to the latest TipRanks data, approximately 4.70% of Ligand Pharma (DE:LGDN) stock is held by public companies and individual investors.
Who owns the most shares of Ligand Pharma (DE:LGDN)?
BlackRock, Inc. owns the most shares of Ligand Pharma (DE:LGDN).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
